We present a 37-year-old man diagnosed with familial dysbetalipoproteinemia who presented with the severe hyperlipidemic phenotype. None of the usual metabolic triggers were found to explain his severe lipid abnormalities. Genetic analysis revealed the expected APOE E2/E2 genotype, but no other mutations were found to explain any monogenic dyslipidemia or syndrome. Polygenic risk scores for quantitative lipid traits did reveal scores placing the patient in the >99th percentile for the general population concerning polygenic susceptibility for both high cholesterol and triglycerides. Owing to his gastrointestinal intolerance to two high-intensity statins, he was treated with both ezetimibe 10 mg a day and evolocumab 140 mg subcutaneously every 2 weeks. All measures of potentially atherogenic lipids were markedly improved and remained so for more than 10 months of follow-up. This case report shows an unusual trigger for severe hyperlipidemia with familial dysbetalipoproteinemia and a favorable therapeutic response to the combination of ezetimibe and evolocumab.
Keywords: Dysbetalipoproteinemia; Evolocumab; Ezetimibe; Hypercholesterolemia; Sitosterolemia; Sterols.
Copyright © 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.